Lifemd, INC Form 4 insider transactions

Joseph Ditrolio, a Director of LifeMD, Inc., received 35,000 shares of common stock on August 11, 2026.

Roberto Simon, a Director of LifeMD, Inc., reported multiple transactions in common stock on December 2, 2024.

Roberto Simon, a Director of LifeMD, Inc., reported multiple transactions in common stock on May 4, 2026.

Calum Archibald Macrae, a Director of LifeMD, Inc., received 35,000 shares of common stock on August 11, 2026.

LifeMD Chief Technology Officer Umesh Sripad was granted 75,000 restricted stock units as part of a long-term incentive plan.

LifeMD CFO Atul Kavthekar was granted 337,500 restricted stock units as part of an equity compensation package.

LifeMD's Chief Marketing Officer, Christopher A. Pisano, was granted 200,000 restricted stock units with a multi-year vesting schedule.

LifeMD's Chief Marketing Officer, Jessica Friedeman, reported the sale of 15,000 shares of common stock at a weighted average price of $3.6105.

LifeMD, Inc. Director John R. Strawn Jr. is set to acquire 22,365 shares of common stock at no cost on October 6, 2025, with vesting scheduled for June 1, 2026.

LifeMD, Inc. Director Joan LaRovere was granted 22,365 restricted shares of common stock, vesting on June 1, 2026, increasing her total beneficial ownership to 107,050 shares.

LifeMD, Inc. Director Joseph DiTrolio was granted 22,365 restricted shares of common stock, vesting on June 1, 2026.

LifeMD, Inc. Director Calum Archibald MacRae was granted 22,365 restricted shares of common stock, vesting on June 1, 2026.

LifeMD, Inc. Director Roberto Simon was granted 22,365 restricted stock units, which are scheduled to vest on June 1, 2026, increasing his total beneficial ownership to 183,175 shares.

LifeMD's Chief Acquisition Officer, Nicholas P. Alvarez, reported a planned sale of 75,000 common shares effective September 10, 2025, at an average price of $5.9168.

LifeMD, Inc.'s Chief Legal Officer, Eric Harold Yecies, acquired 50,000 shares of common stock through the vesting of performance stock on August 22, 2025.

LifeMD's Chief Technology Officer, Dennis Wijnker, acquired 25,000 shares of common stock through a performance stock grant that vested on August 22, 2025.

LifeMD's Chief Accounting Officer, Maria E. Stan, was granted 20,000 shares of common stock as performance-based compensation, vesting on August 22, 2025.

LifeMD, Inc.'s Chief Innovation Officer, Stefan Galluppi, acquired 30,000 shares of common stock through the vesting of performance stock.

LifeMD, Inc.'s Chief Marketing Officer, Jessica Friedeman, was granted 50,000 shares of performance stock that vested on August 22, 2025.

LifeMD, Inc.'s Chief Financial Officer, Marc David Benathen, received a grant of 87,000 shares of common stock as performance-based compensation.

LifeMD's Chief Acquisition Officer, Nicholas P. Alvarez, reported the acquisition of 100,000 common shares through a performance stock grant vesting on August 22, 2025.

LifeMD, Inc.'s Chief Operating Officer, Shayna Webb Dray, acquired 30,000 shares of common stock through a performance stock grant that vested on August 22, 2025.

LifeMD, Inc. Chairman and CEO Justin Schreiber sold 25,000 shares of common stock for approximately $250,000 through a pre-arranged trading plan.

LifeMD's Chief Operating Officer, Shayna Webb Dray, is scheduled to acquire 50,000 restricted stock units, vesting over three years, which will increase her beneficial ownership to 265,000 shares.

LifeMD, Inc. Chairman and CEO Justin Schreiber sold 25,000 shares of common stock on July 1, 2025, at a weighted average price of $13.3783, pursuant to a Rule 10b5-1 trading plan.

LifeMD, Inc.'s Chief Financial Officer, Marc David Benathen, sold a total of 125,000 shares of common stock across two transactions in mid-June 2025, totaling approximately $1.68 million, pursuant to a Rule 10b5-1 trading plan.

LifeMD, Inc.'s Chief Legal Officer and Director, Eric Harold Yecies, sold 15,000 shares of common stock at $12.25 per share, as disclosed in a recent SEC Form 4 filing.

LifeMD, Inc.'s Chief Innovation Officer, Stefan Galluppi, sold 85,000 shares of common stock on June 13, 2025, as part of a pre-scheduled Rule 10b5-1 trading plan.

LifeMD, Inc. Chairman and CEO Justin Schreiber reported the sale of 25,000 shares of common stock for approximately $311,655, executed under a Rule 10b5-1 trading plan.

LifeMD's Chairman and CEO, Justin Schreiber, recently sold shares of the company's common stock, according to a Form 4 filing with the SEC.